Shanghai Kehua Bio-Engineering (002022) Stock Overview

Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic reagents and automatic analyzers in China. It offers signature products, including immunoassay & clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management, and automated comprehensive solutions for nucleic acid blood screening; and immunologic diagnosis products, such as KHB Polaris i1800 full-automatic chemiluminescence immunoassay analysis systems, Polaris i2400 fully automated chemiluminescence immunoassay analysis systems, enzyme linked immunosorbent assay kits, and microplate reader and plate washers. The company also provides biochemical diagnosis products, including ZY Series of automatic clinical chemistry analyzers, Polaris c1000 fully automated modular clinical chemistry analysis systems, and general packaging reagents; and molecular diagnostics products, such as nucleic acid extractors, PCR thermal cyclers, real-time PCR systems, automatic nucleic acid workstations, and compatible kits for extraction and detection; and KHB molecular diagnostics reagents, as well as KHB anti-HIV colloid gold products. It serves hospitals, disease control and prevention centers, blood centers, bio-pharmaceutical enterprises, and scientific research institutions. The company also exports its products. Shanghai Kehua Bio-Engineering Co.,Ltd was founded in 1981 and is headquartered in Shanghai, the People's Republic of China.